Medical Condition News

RSS

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

Politico looks at a new fight brewing over Agent Orange and how it affects programs for Vietnam Veterans. "It's a world turned upside-down from decades ago when returning soldiers had to fight to get attention for deadly lymphomas linked to the herbicide. Now the frailties of men in their 60s — prostate cancer, diabetes, heart disease — lead the list of qualified Agent Orange disabilities, and the result has been an explosion in claims — and the government's liability.

31 Aug 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

$Heparin enoxaparin may provide better outcomes than unfractionated heparin$

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Results from ATOLL, a phase 3 randomised trial comparing two anticoagulants in primary PCI for ST elevation MI, show that the low molecular weight heparin enoxaparin may provide better outcomes in such cases than the traditionally used unfractionated heparin.

30 Aug 2010

Phase 2 INNOVATE PCI trial results for elinogrel presented

Phase 2 trial results for elinogrel, a novel antiplatelet agent available in both intravenous and oral formulations, were presented here today.

30 Aug 2010

Reactivation of CDX2 gene may halt progression of colon cancer

The intestines have to work properly if we are to benefit from the food we eat. Digestive juices must be secreted, the food broken down into smaller components and then transported through the gut wall and onwards to muscles and organs. The lining of the gut is coated in epithelial cells, a specialised layer that produces mucous and hormones while keeping dangerous bacteria and toxins at bay. Close contact with pathogenic microbes and toxins means that the epithelial cells may mutate to form cancer.

30 Aug 2010

BayCare Behavioral Health announces opening of Morton Plant North Bay Hospital Recovery Center in Lutz

As part of its continued commitment to meet the mental health needs of the Tampa Bay community, BayCare Behavioral Health has opened the Morton Plant North Bay Hospital Recovery Center in Lutz.

30 Aug 2010

Canada hosts 13th World Congress On Pain

The Canadian Pain Society (CPS) eagerly welcomes leading pain experts from across Canada and around the globe to the 13th World Congress on Pain in Montreal, Quebec, from August 29 to September 2. Hosted by the International Association for the Study of Pain (IASP), more than 6,000 pain professionals will gather to share their thoughts, research and best treatment practices concerning this throbbing public health issue.

30 Aug 2010

Smoked cannabis relieves chronic neuropathic pain

The medicinal use of cannabis has been debated by clinicians, researchers, legislators and the public at large for many years as an alternative to standard pharmaceutical treatments for pain, which may not always be effective and may have unwanted side effects. A new study by McGill University Health Centre (MUHC) and McGill University researchers provides evidence that cannabis may offer relief to patients suffering from chronic neuropathic pain.

30 Aug 2010

BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.

30 Aug 2010

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.

30 Aug 2010

Positron to host special ASNC 2010 symposium focusing on cardiac PET

Positron Corporation is pleased to announce K. Lance Gould M.D. as the keynote speaker for their upcoming cardiac PET symposium, held at the American Society of Nuclear Cardiology annual meeting, September 23-26 in Philadelphia, PA.

30 Aug 2010

Patients with atherothrombosis are at increased risk of ischemic events: Study

Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

30 Aug 2010

Royal Philips Electronics launches new iE33 xMATRIX cardiac ultrasound system

Royal Philips Electronics today announced the enhanced iE33 xMATRIX cardiac ultrasound system featuring a new ergonomic solution for more efficient adult echocardiograms, the X5-1 transducer. With this enhanced technology, Philips continues its tradition of simplified, patient-focused healthcare solutions by providing a more complete imaging solution.

From Philips Healthcare 30 Aug 2010

Closing ceremony of heart transplant recipient's 700 km bicycle tour across Canada

Media representatives are invited to join us for the closing ceremony of heart transplant recipient Sylvain Bédard's bicycle tour, to take place at the Montreal Heart Institute (MHI). Dr. Michel Pellerin, the cardiac surgeon who performed the operation, will present him with an official MHI shirt as well as a bouquet of flowers to mark his accomplishment: a tour across Canada, 700 kilometres of which were done on bicycle.

30 Aug 2010

Selective lowering of heart rate reduces risk of death and hospitalization: Study

The results of a major international study presented at the European Society of Cardiology Congress in Stockholm and published simultaneously in The Lancet show, for the first time, that selectively lowering heart rate with a novel medication, ivabradine, significantly reduces risk of death and hospitalization for patients with heart failure. This also resolves a longstanding debate about whether lowering heart rate itself can actually lower the risk of heart disease progression.

30 Aug 2010

Homewatch CareGivers releases new guide related to dementia care

As part of its ongoing program to help caregivers and provide families with the information they need to make informed decisions, Homewatch CareGivers has released its latest resource, entitled "Guide to Living with Dementia." This new guide is available for free download from the company's website.

30 Aug 2010

SQI Diagnostics 2010 third quarter net loss increases to $1,613K

SQI Diagnostics Inc.,a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced its financial and operational results for the third quarter ended June 30, 2010.

30 Aug 2010

Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events

Results from the Alpha Omega Trial, a multicentre, placebo-controlled trial in men and women following myocardial infarction (MI), suggest that low doses of n-3 fatty acids given in the form of enriched margarines do not reduce the overall rate of major cardiovascular events.

30 Aug 2010

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

Results from a recent phase 2b clinical trial may provide a new approach to managing excess potassium levels in patients with heart failure and heart failure with chronic kidney disease.

30 Aug 2010

Medical Condition News

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

FDA extends Prescription Drug User Fee Act date for ezogabine

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Phase 2 INNOVATE PCI trial results for elinogrel presented

Reactivation of CDX2 gene may halt progression of colon cancer

BayCare Behavioral Health announces opening of Morton Plant North Bay Hospital Recovery Center in Lutz

Canada hosts 13th World Congress On Pain

Smoked cannabis relieves chronic neuropathic pain

BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

Positron to host special ASNC 2010 symposium focusing on cardiac PET

Patients with atherothrombosis are at increased risk of ischemic events: Study

Royal Philips Electronics launches new iE33 xMATRIX cardiac ultrasound system

Closing ceremony of heart transplant recipient's 700 km bicycle tour across Canada

Selective lowering of heart rate reduces risk of death and hospitalization: Study

Homewatch CareGivers releases new guide related to dementia care

SQI Diagnostics 2010 third quarter net loss increases to $1,613K

Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Latest News